注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Nuvation Bio Inc是一家临床阶段的生物制药公司。该公司致力于开发针对癌症患者的差异化和新型治疗候选者。该公司正在开发六种由药物发现和开发项目产生的全资化合物,包括NUV-422 a细胞周期蛋白依赖性激酶(CDK)抑制剂、NUV-868 a bromodomain和额外末端(BET)抑制剂、NUV-569 a Wee1抑制剂、A2A腺苷受体抑制剂项目和药物-药物结合物(DDC)平台。其主要候选产物NUV-422是一种选择性的CDK 2、4和6小分子抑制剂。其第二个候选产品是NUV-868,一种BD2选择性口服小分子BET抑制剂。其正在发展中,包括NUV-569,NUV-569是一种分化的口服小分子选择性Wee1激酶抑制剂,Wee1激酶是脱氧核糖核酸(DNA)损伤修复的重要调节因子。其子公司包括Nuvation Holdings, LLC和RePharmation Ltd。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
David T. Hung | 63 | 2018 | Founder, President, CEO & Director |
Daniel G. Welch | 63 | 2020 | Independent Chairman of the Board |
Kim D. Blickenstaff | 72 | 2019 | Independent Director |
Robert B. Bazemore | 56 | 2020 | Independent Director |
Wassim Abida | - | 2023 | Member of Scientific Advisory Board |
Johann de Bono | - | 2023 | Member of Scientific Advisory Board |
Junyuan Wang | 51 | 2024 | CEO & Co-Founder of AnHeart Therapeutics and Director |
Kathryn E. Falberg | 63 | 2020 | Independent Director |
Mansoor Raza Mirza | 63 | 2023 | Member of Scientific Advisory Board |
Robert D. Marshal | 64 | 2024 | Independent Director |
Allyson J. Ocean | 51 | 2023 | Member of Scientific Advisory Board |
Xiangmin Cui | 56 | 2024 | Director |
William Anthony Vernon | 68 | 2019 | Independent Director |
Gordon B. Mills | - | 2023 | Member of Scientific Advisory Board |
Joyce Ann O'Shaughnessy | - | 2023 | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核